Photo from wikipedia
Fremanezumab (Ajovy) is a new anti‐CGRP monoclonal antibody therapy indicated for the prophylaxis of migraine in adults. This article outlines its properties, efficacy, adverse effects and place in therapy. Click to show full abstract
Fremanezumab (Ajovy) is a new anti‐CGRP monoclonal antibody therapy indicated for the prophylaxis of migraine in adults. This article outlines its properties, efficacy, adverse effects and place in therapy.
Keywords:
migraine adults;
prophylaxis migraine;
fremanezumab prophylaxis
Journal Title: Prescriber
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Prescriber
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!